Related Experiment Video
Updated: Oct 25, 2025
Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
Published on: May 10, 2024
A therapeutic intervention for Alzheimer's disease using ginsenoside Rg3: its role in M2 microglial activation and
Abstract:
Previously, we have reported that ginsenoside Rg3 has typical activities for neuroprotection and Aβ42 clearance by modulating microglia. In this study, we determined the pivotal role of ginsenoside Rg3 in microglia and neuronal cells. In human microglia, Rg3 and its stereoisomers significantly restored inflammatory M1 to normal M0 state and promoted M2 activation by up-regulating acute cytokines such as interleukin-10 and Arginase 1. Moreover, scavenger receptor type A (SRA) was significantly elevated in the presence of ginsenoside Rg3 and 20(S)-Rg3. This indicated that ginsenoside Rg3 could play a crucial role in Aβ uptake and clearance under activated M2 state. We also observed that soluble amyloid precursor protein-alpha (sAPPα) and ADAM10 levels were increased in APP swe-transfected Nuro-2a neuronal cells, whereas sAPPβ was not processed, suggesting that ginsenoside Rg3 was involved in non-amyloidogenic processing. In immunocytochemistry, SRA and a disintegrin and metalloproteinase 10 (desintegrin and metalloproteinase-containing protein 10, ADAM10) were coincidently upregulated in the presence of ginsenoside Rg3 and its stereoisomers compared to those in normal control. Taken together, these results suggested that ginsenoside Rg3 could boost acute activation of microglia, promote Aβ uptake, and elevate the sAPPα processing under activated M2 state. Although in vivo studies need to be performed, it is certain that ginsenoside Rg3 is highly involved in ameliorating the pathogenesis of neurodegeneration and can be a promising candidate for treating Alzheimer's disease as a new therapeutic intervention.
Insights
Ginsenoside Rg3 modulates microglia to reduce neuroinflammation and amyloid-beta (Aβ) plaque buildup. This natural compound promotes Aβ clearance and non-amyloidogenic processing, showing promise for Alzheimer's disease treatment.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Ginsenoside Rg3 previously showed neuroprotective and Aβ42 clearance effects by modulating microglia.
- Understanding the specific roles of Rg3 in microglia and neuronal cells is crucial for developing Alzheimer's disease therapeutics.
Purpose of the Study:
- To determine the pivotal role of ginsenoside Rg3 in microglia and neuronal cells regarding neuroinflammation and amyloid processing.
- To investigate Rg3's effects on microglial polarization and amyloid-beta (Aβ) uptake.
- To explore Rg3's influence on non-amyloidogenic processing pathways in neuronal cells.
Main Methods:
- Human microglia were treated with Rg3 and its stereoisomers to assess M1/M0/M2 polarization and cytokine expression.
- APP swe-transfected Nuro-2a neuronal cells were analyzed for changes in amyloid precursor protein processing.
- Immunocytochemistry was used to evaluate the expression of scavenger receptor type A (SRA) and ADAM10.
Main Results:
- Ginsenoside Rg3 shifted microglia from inflammatory M1 to M0 state and promoted M2 activation, up-regulating interleukin-10 and Arginase 1.
- Rg3 significantly elevated scavenger receptor type A (SRA) expression, indicating enhanced Aβ uptake capacity.
- In neuronal cells, Rg3 increased soluble amyloid precursor protein-alpha (sAPPα) and ADAM10 levels, favoring non-amyloidogenic processing.
Conclusions:
- Ginsenoside Rg3 activates microglia towards an anti-inflammatory M2 phenotype, enhancing Aβ clearance.
- Rg3 promotes non-amyloidogenic processing of amyloid precursor protein in neuronal cells.
- Ginsenoside Rg3 is a promising therapeutic candidate for Alzheimer's disease, warranting further in vivo investigation.
More Related Videos
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...